New drug applications approved by US FDA as of 1 - 15 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The true prevalence of benign prostatic hyperplasia (BPH) in male populations has been difficult to estimate due to the lack of a standardized definition. However, the characteristic features of BPH – abnormal proliferation of stromal and epithelial prostatic cells – become more common in men with age. The following article highlights the benefits of dutasteride/tamsulosin (Duodart®, GlaxoSmithKline), a combination treatment consisting of two drugs with complementary mechanisms of action, in patients with BPH.
At least one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) has high individual vaccine effectiveness (VE) in preventing invasive pneumococcal disease (IPD) in a paediatric population with suboptimal vaccination coverage, a new study has shown.